Senseonics Holdings, Inc. (SENS) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents mixed signals: while there are positive aspects such as increased revenues, strong retention rates, and seamless transitions, these are counterbalanced by increased expenses, net losses, and vague guidance on partnerships. The Q&A section highlights concerns over partnership timelines and cost efficiencies. The lack of clear guidance and the increase in expenses and net loss weigh down the overall sentiment, leading to a neutral prediction for the stock price movement over the next two weeks.
Key Financial Performance
Revenue $11.7 million in Q1 2026, an 85% increase year-over-year from $6.3 million in Q1 2025. This growth was driven by continued momentum of Eversense 365 new patient additions, retention rates slightly above plan, and a shift to the more profitable bundled pay reimbursement channel.
Gross Margin 58% in Q1 2026, up from the prior year. This improvement was attributed to higher manufacturing volumes, the structural benefit of eliminating the Ascensia revenue share, and a shift to the bundled pay channel.
Gross Profit $6.9 million in Q1 2026, an increase of $5.4 million from the prior year period. This was due to higher U.S. revenues, higher average selling prices, and a more streamlined manufacturing and supply chain.
Research and Development Expenses $8.6 million in Q1 2026, an increase of $1.3 million year-over-year. The increase was primarily due to new R&D projects, the ramp-up of new clinical trials, and increased headcount to support these activities.
Selling, General and Administrative Expenses $30.2 million in Q1 2026, an increase of $22.5 million year-over-year from $7.7 million in Q1 2025. This increase was driven by the integration of the commercial organization, including increased personnel, transition support services from Ascensia, direct-to-consumer marketing, and other operational costs.
Net Loss $32.3 million in Q1 2026, compared to $14.3 million in Q1 2025. The increase in net loss was primarily due to increased expenses resulting from the costs related to taking over the commercialization and distribution of Eversense.
Cash, Restricted Cash, and Cash Equivalents $64.6 million as of March 31, 2026. This reflects the company's strengthened balance sheet following recent financing initiatives.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Eversense 365: Continued strong adoption in the U.S. with direct-to-consumer (DTC) shipments nearly doubling year-over-year in Q1 2026. Launched in Europe with initial patients in Sweden and Spain, and upcoming launches in Germany and Italy. Integration with Sequel Med Tech's twiist insulin pump as the first automated insulin delivery system with a year-long CGM.
Gemini and Freedom development programs: Gemini targeted for launch in the first half of 2027, offering a 1-year sensor with a battery for continuous and optional on-demand readings. Freedom to begin first in-human trials in the second half of 2026, featuring a 1-year sensor with built-in Bluetooth for direct connection to phones and insulin pumps.
Eversense 365 app enhancements: New app features, including advanced AI, are under development and expected to launch later in 2026.
European market expansion: Launched Eversense 365 in Sweden and Spain, with Germany and Italy launches underway. Transitioning Ascensia's European commercial organization to Senseonics.
U.S. market growth: Direct-to-consumer channel accounted for 60% of new patient shipments in Q1 2026. Eon Care expanded to 34 states, performing over 1/3 of all Eversense insertions and reducing geographic barriers for CGM adoption.
Integration of U.S. commercial organization: Completed transition from Ascensia Diabetes Care, aligning sales strategy, field execution, and market access priorities. Resulted in improved financial performance and operational efficiency.
Eon Care expansion: Expanded to 34 states with over 70 nurses performing insertions, aiming for 100 nurses by year-end. Provides scalable service infrastructure for CGM adoption.
Financial strengthening: Raised over $100 million through equity financing and expanded debt facility. Positioned to support product development and commercialization through 2028.
Focus on bundled pay reimbursement: Shifted 60% of U.S. volume to the more profitable bundled pay channel, contributing to improved gross margins.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory and Compliance Risks: The company acknowledges risks and uncertainties related to regulatory matters, as highlighted in their forward-looking statements disclaimer. These could impact product approvals and market entry timelines.
Financial Risks: The company reported a net loss of $32.3 million in Q1 2026, an increase from the prior year, primarily due to increased expenses from commercialization and distribution efforts. Cash utilization is expected to be between $110 million and $120 million for 2026, which could strain financial resources.
Operational Risks: The integration of the U.S. and European commercial organizations poses challenges, including the need to finalize business systems, transfer contracts, and hire additional roles. Any delays or inefficiencies could disrupt operations.
Market and Competitive Risks: The company faces competitive pressures in the continuous glucose monitoring (CGM) market. The success of their Eversense 365 product and future pipeline depends on market adoption and differentiation from competitors.
Supply Chain and Manufacturing Risks: The company is scaling manufacturing processes for future products like Gemini and Freedom. Any disruptions or inefficiencies in scaling could delay product launches and impact financial performance.
Economic and Reimbursement Risks: The business is seasonal, with revenue heavily weighted towards the second half of the year. Additionally, reliance on bundled pay reimbursement channels, which account for 60% of volume, could pose risks if payer dynamics change.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Full Year 2026 Global Net Revenue Guidance: Raised to $60 million to $64 million from $58 million to $62 million, representing year-over-year growth of 70% to 82%.
Eversense 365 Adoption: Anticipates doubling U.S. patients in 2026, with strong growth in direct-to-consumer and healthcare professional channels.
European Market Expansion: Launching Eversense 365 in Sweden, Spain, Germany, and Italy, with initial patient insertions already underway in Sweden and Spain.
Eon Care Expansion: Plans to grow the network of nurses to 100 by the end of 2026, expanding geographic reach and increasing share of insertion procedures.
Automated Insulin Delivery Integration: Continued integration of Eversense 365 with automated insulin delivery systems, including the twiist insulin pump, with additional partnerships being pursued.
Product Pipeline Development: Gemini launch targeted for the first half of 2027 and Freedom product to enter first human trial in the second half of 2026.
Gross Profit Margin Guidance: Expected to be between 55% and 58% for full year 2026, increasing in the back half of the year.
Operating Expenses and Cash Utilization: Operating expenses expected to be between $150 million and $160 million, with cash utilization between $110 million and $120 million in 2026.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How has the transition of Ascensia in the U.S. been, and are there any anticipated lags in their contribution to patient growth?
A:The transition has been seamless in the U.S., with sales reps continuing their efforts without any lag. However, there might be some lag in the four European countries as they transition from BGM sales efforts to hiring new sales reps.
Q:What is the cadence of investments following the capital raise, and how will it impact new patient growth?
A:The original plan includes an increase in DTC spending in the back half of the year, maintaining a $13 million budget. The sales force will remain at 43 territories, with plans to expand in the future. The investments are expected to drive new patient growth.
Q:What is the current mix of insertions through the bundled pay channel, and how is it expected to evolve?
A:Currently, 60% of insertions are through the bundled pay channel, up from 50% historically. This mix is expected to transition gradually over a couple of years, with a focus on Medicare and commercial payers.
Q:Are there any updates on partnership discussions for Eversense 365 and the Freedom program?
A:Partnership discussions for Eversense 365 are ongoing, with no announcements yet. For the Freedom program, progress has been made, and a feasibility study outside the U.S. is planned for the second half of the year, followed by discussions with the FDA for a pivotal study.
Q:What are the retention rates for Eversense 365, and are there any changes observed?
A:Retention rates remain strong, with first-to-second sensor retention at 75%, second-to-third at 85%, and third sensor retention well into the 90s. Early data for the one-year sensor is encouraging and slightly stronger than expected.
Q:What is the status of the next-gen battery platform and its associated risks?
A:The next-gen battery platform, sourced from Integer, has no technological risk as it uses well-known chemistry. The Gemini product with the battery is already in clinical study, and the Freedom product is ready for human trials with ongoing refinements to Bluetooth technology.
Q:Have there been any changes in the cost per patient acquisition through DTC channels post-Ascensia transition?
A:The cost per workable lead has improved in 2026 compared to the back half of 2025. Investments are now spread throughout the year, leading to better efficiency and conversion rates.
Q:How does Eversense 365 defend its value proposition against competitors with shorter-duration sensors?
A:Eversense 365 offers a year-long sensor, reducing the need for frequent changes and allowing users to focus less on diabetes technology. This simplicity and ease of use make it attractive despite competitors' shorter-duration sensors.
Q:What was the reception of the data presented at the ATTD conference on Eversense 365 and Sequel pump users?
A:The data received positive feedback, showcasing strong time-in-range and GMI results. Efforts are underway to publish the data in a peer-reviewed journal for broader visibility.
Q:Does the data from Sequel pump users help in advancing partnership discussions?
A:Yes, the success and data from the combined system have positively influenced partnership discussions, substantiating the product's performance and aiding conversations.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the timeline for partnership announcements for Eversense 365 and the Freedom program, using vague language like 'ongoing discussions' and 'making progress.' Additionally, they did not provide precise data on the cost per patient acquisition or the exact improvements in conversion rates post-Ascensia transition.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Ascensia
CGM
DTC patient
Eon Care
Eversense
Germany Italy
Spain
Sweden
adoption
balance sheet
debt
expansion
facility
financing
health care
increase
insertion
insulin
integration
launch
loss
manufacturing
margin
market
momentum
nurse
offering
pay channel
period
progress
reimbursement channel
reorder
sale channel
sensor
system
transition
user
volume
SENS Transcript
Senseonics Holdings, Inc. (SENS) Q1 2026 Earnings Call Transcript
Unknown5-8
The earnings call presents mixed signals: while there are positive aspects such as increased revenues, strong retention rates, and seamless transitions, these are counterbalanced by increased expenses, net losses, and vague guidance on partnerships. The Q&A section highlights concerns over partnership timelines and cost efficiencies. The lack of clear guidance and the increase in expenses and net loss weigh down the overall sentiment, leading to a neutral prediction for the stock price movement over the next two weeks.
Senseonics Holdings, Inc. (SENS) Q4 2025 Earnings Call Transcript
Positive3-2
The earnings call summary shows a positive sentiment with a 20% revenue increase and improved gross margins. Despite a net loss, it has narrowed significantly, indicating better cost management. The strategic plan outlines growth expectations and new product launches, which are promising. The lack of clear management responses in the Q&A is a concern but not enough to offset the positive financials and strategic outlook. Overall, the sentiment is positive, anticipating a stock price increase of 2% to 8%.
Senseonics Holdings, Inc. (SENS) Q3 2025 Earnings Call Transcript
Positive11-5
The earnings call highlights strong financial performance with improved gross margins and reduced net loss. The company is expanding its market presence with product launches in Europe and increased DTC marketing spend. Despite some uncertainties in timelines and payer transitions, the guidance is optimistic with expected patient growth and revenue. Positive trends in patient acquisition and competitive dynamics further support a positive outlook. The Q&A section indicates management's confidence in growth opportunities, although some details were vague. Overall, the sentiment is positive, likely leading to a stock price increase of 2% to 8%.
Senseonics Holdings, Inc. (SENS) Q2 2025 Earnings Call Transcript
Positive8-6
The earnings call shows strong financial performance with a 37% increase in net revenue and improved gross profit margins. Despite a net loss, the company reduced R&D expenses and increased cash position through public offerings. The Q&A section highlights positive retention rates and potential growth from the consignment program and Eon Care. However, there are uncertainties in retention data for the 365 version and revenue impact from Eon Care. Overall, the financial results and strategic initiatives suggest a positive stock price movement in the short term.
SENS Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
